Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.
The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor.
Recruitment for the study has begun globally with the first patients enrolled in Australia, the companies said.
Moderna and Merck started a late-stage study in July testing the combination therapy in patients with melanoma, the most deadly form of skin cancer.
https://finance.yahoo.com/news/1-moderna-merck-begin-stage-122013822.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.